Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.76 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.76 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.76 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.76 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.76 |
| ▸ | ATIC | P31939 | 3/20 | 0.76 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.76 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.76 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.76 |
| ▸ | FRK | P42685 | 1/20 | 0.76 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL108860 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3760710 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934793 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL577951 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL21600667 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15569564 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2549428 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174991-B2 | Crystalline form of pemetrexed disodium | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2015-11-03 | — | — | US | claimed |
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | UNIVERSITY OF ZURICH (CH) | 2012-12-27 | — | — | US | claimed |
| CN-101417998-B | Purification method of pemetrexed salt | CHONGQING PHARM RES INST CO | 2012-10-24 | — | — | CN | claimed |
| EP-2504341-A1 | A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | Azad Pharmaceutical Ingredients AG (CH) | 2012-10-03 | — | — | EP | claimed |
| WO-2011064256-A1 | A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2011-06-03 | — | — | WO | claimed |
| CN-101417998-A | Purification method of pemetrexed salt | CHONGQING PHARM RES INST CO (CN) | 2009-04-29 | — | — | CN | claimed |
| CN-119950395-A | Local, sustained, controlled release implantable reservoirs for therapeutic agents for the treatment of cancer and related symptoms and conditions | 铸造疗法股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2025-01-02 | — | — | US | disclosed |
| US-12109232-B2 | Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier | KORTUC INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| EP-4420666-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | Kyushu University, National University Corporation (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240165016-A1 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2024-05-23 | — | — | US | disclosed |
| US-20240092953-A1 | NOVEL COPOLYMER | KOWA COMPANY, LTD. (JP) | 2024-03-21 | — | — | US | disclosed |
| CN-117693334-A | Pemetrexed disodium liquid composition, preparation method and application thereof | 上海云晟研新生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-06-12 | — | — | US | disclosed |
| WO-2008021411-A2 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | SICOR INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060079480-A1 | Novel antifolate combination therapies | NIYIKIZA CLET | 2006-04-13 | — | — | US | disclosed |
| US-20030212038-A1 | Novel antifolate combination therapies | ELI LILLY AND COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1313508-A2 | COMBINATION CONTAINING AN ANTIFOLATE AND METHYLMALONIC ACID LOWERING AGENT | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002101391-A2 | METHOD OF USE | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002002093-A2 | COMBINATION CONTAINING AN ANTIFOLATE AND METHYLMALONIC ACID LOWERING AGENT | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | CD274, PDCD1, PDCD1LG2 | GART 3791/4885DHFR 3535/4885TYMS 2625/4885 |
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | TYMP, TYMS, MTHFD1 | GART 149/4885DHFR 11/4885TYMS 2/4885 |
| US-20240092953-A1 | NOVEL COPOLYMER | CX3CR1, CXCR4, SSTR3 | GART 4464/4885DHFR 194/4885TYMS 1499/4885 |
| US-20240165016-A1 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | SLC19A1, FOLR2, SLC29A1 | GART 222/4885DHFR 31/4885TYMS 34/4885 |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | DCTD, DPYD, PDCD2L | GART 77/4885DHFR 19/4885TYMS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.